Aortic stenosis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SGLT2 0
• PCSK9 3
• TTR 1
• GLP-1 0
• APOE 0
• NRF2 0
• AMPK 0
• EGFR 0
• ERK 0
• MAPK 0
• PI3K 0
• STAT3 0
• ACE2 0
• AKT 0
• BCL-2 0
• BRAF 0
• CD40 0
• CXCR4 0
• DPP-4 0
• IL-6 0
• mTOR 0
• PPAR 0
• STING 0
• TNF 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R01

  Risk Prediction for aortic stenosis and the impact of statin therapy among adults >75 years old in the PREVENTABLE trial

  Johns Hopkins University· Baltimore, Egyesült Államok· 632 235 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NHLBI · R01

  The Cellular and Molecular Role ofGATA4 in Bicuspid Aortic Valve Disease

  University of Arizona· Tucson, Egyesült Államok· 726 242 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NHLBI · F32

  Characterizing Neoaortic Valve Biomechanics in the Ross Procedure

  Stanford University· Stanford, Egyesült Államok· 81 580 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NHLBI · K08

  Multi-omic evaluation of atherogenic and non-atherogenic mechanisms and risk in calcific aortic valve disease

  Brigham and Women's Hospital· Boston, Egyesült Államok· 167 400 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NHLBI · R01

  Optimized development of novel leaflet biomaterials for replacement heart valves

  University of Texas at Austin· Austin, Egyesült Államok· 1 296 842 USD awarded in fiscal year 2026· until 2029. máj.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  EuroHeartPath: Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes

  Universitair Medisch Centrum Utrecht· Utrecht, Hollandia· EU contribution 14 979 063 EUR· until 2030. jan.· 10 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis (CHIP-AVS)

  Johann Wolfgang Goethe-Universitaet Frankfurt Am Main· Frankfurt Am Main, Németország· EU contribution 2 225 906 EUR· until 2027. okt.

7 of 38 running projects, newest first. Listed amounts together: 18,8 M USD + 17,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease

  NCT06996223· Nanfang Hospital, Southern Medical University· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 19
• Gene Expression Profiling 20
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 5
• Proteomics 10
• Metabolomics 4
• Immunohistochemistry 3
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 47
• Machine Learning 24
• Deep Learning 17
• Cohort Studies 40
• Genome-Wide Association Study 18

• Aortic Stenosis Hyalectan Remodeling Revealed by Proteomics and Glycoproteomics.

  Arterioscler Thromb Vasc Biol, 2026. júl.

• Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis.

  Cardiovasc Drugs Ther, 2026. júl.

• Harnessing Large-Scale Multi-Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population.

  Adv Sci (Weinh), 2026. júl.

• Changes in cardiac myosin acetylation disrupt the super-relaxed state in genotype-negative hypertrophic cardiomyopathy with type 2 diabetes.

  Cardiovasc Diabetol, 2026. máj.

• Proteomic profiling identifies molecular subtypes and unveils mechanistic insights into clinical features of hypertrophic cardiomyopathy.

  J Transl Med, 2026. máj.

• Proteomic and degradomic signatures of extracellular matrix remodeling in calcific aortic valve stenosis.

  Mol Med, 2026. máj.

• Mitochondrial Extracellular Vesicles Enhance Aortic Valve Calcification Via Carnitine O-Octanoyltransferase-Brief Report.

  Arterioscler Thromb Vasc Biol, 2026. máj.

• Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy.

  Circ Genom Precis Med, 2026. ápr.

• Genetic insights into radiomic and proteomic changes under β1-blockers treatment in hypertensive heart disease and hypertrophic cardiomyopathy.

  BMC Med, 2026. febr.

• Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.

  Circ Heart Fail, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.